The Texas Screening Alliance for Cancer Therapeutics formed in 2011 as a result of a multi-institution award from the Cancer Prevention and Research Institute of Texas to bring high-throughput technologies to cancer scientists in the state of Texas. For more information click here.
Texas A&M Health Science Center
Dr. Peter Davies is a distinguished pharmacologist and molecular endocrinologist who has served as the Co-Director of the John S. Dunn Gulf Coast Consortium for Chemical Genomics since its inception in 2003. In addition, he serves as a member of the Oversight Committee of the Gulf Coast Consortia and as chair of the Research Consortia Committee. Dr. Davies is a Professor and Alkek Chair, the Director of the Center for Translational Cancer Research, and Executive Director of the Institute of Biosciences and Technology for Texas A&M Health Science Center. Previously, Dr. Davies was a Professor in Medicine and served as the Provost and Executive Vice-President for Research at UTHealth. The author of more than 130 peer-reviewed publications, Dr. Davies’ scientific interests have included extensive studies on the molecular basis of hormone and drug action with a particular emphasis on the biology and pharmacology of retinoids.
UT MD Anderson Cancer Center
Dr. Geoffrey Bartholomeusz is an assistant professor in the Department of Experimental Therapeutics at UT M.D. Anderson Cancer Center and serves as the Director of the GCC / UT M.D. Anderson Cancer Center siRNA Screening Services Laboratory. For the past 11 years he has been involved in research related to the elucidation of the signaling pathways associated with the induction of cancer and for the last three years has served as the Director of the siRNA Screening Laboratory. In this capacity, he has been instrumental in establishing the screening program, and overseeing the completion of 39 genomic screens (with 10 more genome-wide screens currently in the pipeline).
The University of Texas at Austin
Dr. Kevin Dalby is a Professor in the Division of Medicinal Chemistry, College of Pharmacy, University of Texas at Austin. His research laboratory is a multi-disciplined laboratory that encompasses, organic chemistry, biochemistry, enzymology and cell biology. For the last 13 years the Dalby laboratory has been interested in understanding the regulation of protein kinases with a particular focus on the MAP kinases. Current projects include computer-aided inhibitor design of non-ATP competitive MAPK inhibitors aided by high-field protein NMR. In recent years the Dalby laboratory has also initiated high throughput screening projects aimed at identifying small molecule discovery projects in collaboration with groups in the Department of Experimental Therapeutics at MD Anderson.
Dr. Daniel Carson is a distinguished biochemist and molecular endocrinologist who is the Dean, Wiess School of Natural Sciences, Rice University and Schlumberger Chair of Advanced Studies and Research and Professor of Biochemistry and Cell Biology at Rice University. The author of more than 160 peer reviewed publications and an NIH MERIT award recipient, Dr. Carson's scientific interests include the molecular basis of embryo implantation and the regulation of expression and function of cell surface glycoproteins and extracellular matrix components.
Baylor College of Medicine
Dr. Michael Mancini is a Professor in the Department of Molecular & Cellular Biology, Baylor College of Medicine (BCM), and director of the Integrated Microscopy Shared Resource of the Dan L. Duncan Cancer Center at BCM. Dr. Mancini is the co-founder and co-director of the John S. Dunn Gulf Coast Consortium for Chemical Genomics. He is a member of the BCM Graduate School for Biomedical Sciences and active member of graduate programs in Molecular and Cellular Biology, and Structural and Computational Biology & Molecular Biophysics; he has trained ~30 undergraduate, graduate and postdoctoral members in his laboratory. Dr. Mancinci has been a pioneer in the development and application of high throughput microscopy (HTM) to quantitative analysis of cell function and to drug discovery research. These studies have led to the development of a novel, fully automated “ultra”-HCA approach to that can be applied to small molecule and RNAi screening applications. Dr. Mancini’s laboratory uses high resolution light microscopy, time lapse studies, and biophysical measurements of nuclear protein mobility to develop single cell assays to study the activity of steriod receptors and receptor co-regulators in breast and prostate cancer cells.
Texas A&M Health Science Center
Dr. Cliff Stephan is an assistant professor of Center for Translational Cancer Research at Texas A&M Health Science Center and serves as the Director of the GCC Chemical Genomics Central Screening Laboratory. He is a vascular biologist with extensive experience in pharmacology and drug discovery having served, from 1999 -2007 as the Director of New Drug Discovery and High Throughput Screening at Encysive Pharmaceuticals. In this capacity he was responsible for all high throughput screening programs at the company including new target identification and validation, small molecule screening campaigns, data acquisition and analysis. The Encysive screening group was responsible for running 8-12 full 100,000 compound screens per year for drug discovery. Since 2007 he has served as the Director of the John S Dunn high-throughput and high-content screening core laboratory of the GCC for Chemical Genomics, supervising the completion of 9 full screening campaigns with 4 currently in progress. Dr. Stephan lectures regularly on drug discovery in graduate programs and has organized GCC workshops on high-throughput screening and its application to drug discovery research.
The Methodist Hospital Research Institute
Dr. Stephen T.C. Wong is John S Dunn Distinguished Endowed Chair of Biomedical Engineering; Chairman of Department of Systems Medicine and Bioengineering, Principal Investigator of The NCI Center for Modeling Cancer Development (CMCD), the Center for Bioengineering and Informatics (CBI), and TH and WF Chao Center for Bioinformatics Research and Neurosciences Imaging (BRAIN) at The Methodist Hospital Research Institute (TMHRI); Vice Chairman of Radiology and Chief of Medical Physics, The Methodist Hospital System; and Professor of Radiology, Neurology, Neurosciences, Pathology, and Laboratory Medicine at Weill Cornell Medical College of Cornell University. Dr. Wong is a world leader in bioinformatics, image computing, systems biology, high content screening, and databases. Dr. Wong has over two decades of research and leadership experience in academic medicine and private industries. His earlier work was in industry, focused on the development of VLSI and optoelectronics computer chips, imaging information management systems, and eCommerce solutions. In 2002, he returned to academia and founded the HCNR Center for Bioinformatics at Harvard Medical School (HMS) and the Center for Functional and Molecular Imaging Center at Brigham and Women’s Hospital, Harvard Partners. During his tenure at Harvard, he collaborated closely with two drug screening centers there, ICCB (Institute of Chemistry and Cell Biology) at HMS and LDDN (Laboratory for Drug Discovery in Neurodegeneration) at the Harvard Neurodiscovery Center in establishing HTS/HCS programs for cancer and neurodegeneration. Currently his group at TMHRI focuses on fast track drug repositioning for cancer, neurodegeneration, and rare diseases.
Administrative Coordinator and Executive Assistant to Peter Davies
Texas A&M Health Science Center
Research Program Director
Education & Information Exchange Core